TLR7 and COVID-19: Here, we demonstrate that a synthetic cis-bindingSiglec-9 agonist(pS9L, Figure 2b)40 inhibits NETosis in primary neutrophils in modelsof local (TLR-7/8 agonist) and peripheral (COVID-19 plasma) COVID-19-associatedinflammation.